Skip to main content
Premium Trial:

Request an Annual Quote

Samples Available for sPRG 2012 PTM Study


The Proteomics Standards Research Group of the Association of Biomolecular Resource Facilities has announced the availability of samples for its 2012 study.

The study, which is the second part of a multi-year project and builds on the phosphorylation standard study conducted last year by sPRG, is aimed at building a standard for the assessment of capabilities for detection and identification of a variety of post-translational modifications in a complex proteome sample and the development of new approaches for the characterization of post-translationally modified proteins.

Last year's study sample contained only O-phosphorylated peptides and their unmodified counterparts. The current sample, which comprises a total of 71 modified peptides, includes a larger set of singly and multiply phosphorylated peptides as well as sulfates, methylated, acetylated, and nitrated tryptic peptides.

Participating researchers will be asked to submit detailed identification results, upload acquired raw LC-MS/MS data files supporting their identifications, and complete an online survey. Results from the study will be presented at the ABRF 2012 meeting.

Requests for samples should be submitted to [email protected] before July 10 and results submitted by Sept. 1.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.